About: Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 16 September 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2013 (ast) наукова стаття, опублікована у вересні 2013 (uk) مقالة علمية نشرت في 16 سبتمبر 2013 (ar) scientific article published on 16 September 2013 (en)
publication date	wds:Q37582317-D8A8377F-B5E0-4E38-A444-F73F8BAA9318
publication date	2013-09-16 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37582317-95A62E5D-F5A6-48CD-807E-A8EAFDDB6C96
language of work or name	English
cites work	wds:Q37582317-032B4472-A56C-4DF9-9628-3972AF0B1D20 wds:Q37582317-1B34FFEC-D76B-46C8-8E80-9E564C4ACE70 wds:Q37582317-1B682EB0-0D55-426A-8494-A90664C79002 wds:Q37582317-2F018F0B-7793-4AF0-940F-5FC50DA3B9A1 wds:Q37582317-60422424-2D3B-4AE1-9A88-F85322FCB3E7 wds:Q37582317-68C40E97-5489-4E3F-A36B-1761877DFCDA wds:Q37582317-6ADCCDB2-3820-42AB-A76A-F83E4DA71C7E wds:Q37582317-79250FEA-5874-46E7-AD30-78540F0413C9 wds:Q37582317-7BEE1CB9-8910-415B-A951-12B0E7034C8A wds:Q37582317-829C9075-5050-47DC-B35B-747A87F09D09 wds:Q37582317-86391C11-C1B4-4FB9-8F4F-3DA056B7EC71 wds:Q37582317-8BE97743-6AF7-46B5-820D-4C65AFF8EB01 wds:Q37582317-8F73CC81-FAA7-4646-96DA-299DAEF1E202 wds:Q37582317-A74B29A7-9599-4A9A-AAD5-98D1E58B804E wds:Q37582317-B05BBE0C-CE51-48FA-83CC-088A7CF39142 wds:Q37582317-BCBE8671-E043-442C-B787-60642199B658 wds:Q37582317-C8E3EF57-6A86-46D7-A968-8A437B81E0BE wds:Q37582317-CB638129-94CF-4CA7-9721-7D8F307E29EC wds:Q37582317-D2E95E5B-89C2-4288-998E-D4E7E49B3213 wds:Q37582317-DDB4CBD9-43A3-4E4B-9E51-A387200215F0 wds:Q37582317-FA53D7BB-CD43-4DAB-A778-0CE2777A6CA9 wds:Q37582317-FAA4A6A9-9382-4063-BD91-1CCB2D155296 wds:Q37582317-FD8106A0-28EB-406D-8DB1-3A4E71AA95CD
cites work	Claudin association with CD81 defines hepatitis C virus entry. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors Identification of scavenger receptor SR-BI as a high density lipoprotein receptor Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Human occludin is a hepatitis C virus entry factor required for infection of mouse cells Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Telaprevir for previously untreated chronic hepatitis C virus infection Boceprevir for untreated chronic HCV genotype 1 infection Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus and Host A genetically humanized mouse model for hepatitis C virus infection Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection
author name string	wds:Q37582317-081A02D8-4B5D-47AA-A2D7-787479C17245 wds:Q37582317-0AB35579-18FB-4234-B533-76393E0C82D9 wds:Q37582317-0E516B11-5766-4827-A163-18581D4C845E wds:Q37582317-1B4FDBDF-E5CE-4153-B6CF-ABDC2AF2B264 wds:Q37582317-29FDF6B6-7561-4750-A5C3-F539D662BC88 wds:Q37582317-48714407-36DF-4A29-AD44-766CDCE94DEB wds:Q37582317-6E1E2C11-264E-4C3B-89D2-3856F77BF386 wds:Q37582317-DB56C890-B02E-44E2-8DDB-60929BD613D0
author name string	Marshall J Glesby Roy Matining Minhee Kang Debika Bhattacharya Victoria A Johnson Valerianna Amorosa Kristine Coughlin AIDS Clinical Trials Group A5277 Protocol Team
rdfs:label	Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study (en) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study (ast) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. (nl)
skos:prefLabel	Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study (en) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study (ast) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. (nl)
name	Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study (en) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study (ast) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. (nl)
author	wds:Q37582317-0E45A3F8-E4A1-4E24-934A-3CEEB38311CD wds:Q37582317-3BA00790-C0F3-4D44-A0BC-995EC4890F1E wds:Q37582317-B5C0723A-78F7-4D65-94DB-CB44AFDEE990 wds:Q37582317-D8F12FE2-8A7E-4329-A521-26CE75F9BCB6
author	Flossie Wong-Staal David L Wyles Mark Sulkowski Gene D Morse

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software